leuprolide

(redirected from Eligard)
Also found in: Dictionary, Wikipedia.
Related to Eligard: Lupron

leuprolide

 [loo-pro´līd]
a synthetic analogue of gonadotropin-releasing hormone, used in the form of the acetate ester as an antineoplastic agent, treatment for endometriosis, and gonadotropin inhibitor. Administered subcutaneously or intramuscularly.

leuprolide

/leu·pro·lide/ (loo-pro´līd) a synthetic analogue of gonadotropin-releasing hormone, used in the form of the acetate ester as an antiendometriotic agent, antineoplastic, and gonadotropin inhibitor.

leuprolide

(lo͞o′prō-līd′)
n.
A drug that is a synthetic polypeptide analog of naturally occurring gonadotropin-releasing hormone, C29H84N16O12, used in its acetate form to treat advanced prostate cancer.

leuprolide

Viadur® An analogue of gonadotropin-releasing hormone, which has been used to manage PMS, and block ovarian or testicular hormone production in Pts with hormonally active CA. See PMS.
References in periodicals archive ?
In January 2002, Atrix received United States Food and Drug Administration approval for Eligard 7.
Atrix's marketing partner for the Eligard product line, anticipates this new therapy will be an important addition in the fight against prostate cancer.
This new patent is specific to the composition of our proprietary Atrigel drug delivery system with leuprolide acetate, the active component in our Eligard prostate cancer products.
For complete ELIGARD prescribing information, please go to: http://tolmar.
The company's biggest contributor to revenue growth during 2002-2006 was product sales of Visudyne and Eligard.
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact [sanofi-aventis, Laval, QC], Eligard [sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc.
This is the second MAA MediGene has submitted for the Eligard products -- in December of 2001 they submitted an MAA for the 7.
Table 19: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 65
Table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 62
Medications in the GnRH class are marketed under the brand names Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex.
is Eligard 45 (leuprolide acetate for injectable suspension), a 6-mo palliative hormone treatment for advanced prostate cancer.
Worldwide Eligard sales in the second quarter were $67.